Recent progress on nutraceutical research in prostate cancer

Cancer and Metastasis Reviews

Volumn 33, Issue 2-3, 2014, Pages 629-640

  Li, Yiwei ^a   Ahmad, Aamir ^a   Kong, Dejuan ^a   Bao, Bin ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; AR; Cancer stem cell; NF B; Nutraceuticals; Prostate cancer

Indexed keywords

ANIMAL; CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; DRUG EFFECTS; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; RESEARCH; RISK; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; HUMANS; MALE; PROSTATIC NEOPLASMS; RESEARCH; RISK; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84905112120     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9478-9     Document Type: Article

References (104)

1. Siegel, R., Naishadham, D., & Jemal, A. (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30.
2. Kolonel, L. N., Hankin, J. H., Whittemore, A. S., et al. (2000). Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev, 9, 795-804. (Pubitemid 30660052)
3. Namiki, M., Akaza, H., Lee, S. E., et al. (2010). Prostate cancer working group report. Jpn J Clin Oncol, 40(Suppl 1), i70-i75.
4. Brower, V. (1998). Nutraceuticals: poised for a healthy slice of the healthcare market? Nat Biotechnol, 16, 728-731.
5. Yan, L., & Spitznagel, E. L. (2009). Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am J Clin Nutr, 89, 1155-1163.
6. Jacobsen, B. K., Knutsen, S. F., & Fraser, G. E. (1998). Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control, 9, 553-557. (Pubitemid 29046127)
7. Kurahashi, N., Iwasaki, M., Sasazuki, S., et al. (2007). Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev, 16, 538-545. (Pubitemid 46548658)
8. Lee, M. M., Gomez, S. L., Chang, J. S., et al. (2003). Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev, 12, 665-668. (Pubitemid 36899850)
9. Liu, B., Mao, Q., Cao, M., et al. (2012). Cruciferous vegetables intake and risk of prostate cancer: a meta-analysis. Int J Urol, 19, 134-141.
10. Cohen, J. H., Kristal, A. R., & Stanford, J. L. (2000). Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst, 92, 61-68. (Pubitemid 30082230)
11. Richman, E. L., Carroll, P. R., & Chan, J. M. (2012). Vegetable and fruit intake after diagnosis and risk of prostate cancer progression. Int J Cancer, 131, 201-210.
12. Kirsh, V. A., Peters, U., Mayne, S. T., et al. (2007). Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst, 99, 1200-1209. (Pubitemid 47233070)
13. Gann, P. H., Ma, J., Giovannucci, E., et al. (1999). Lower prostate cancer risk inmen with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res, 59, 1225-1230. (Pubitemid 29136251)
14. Lu, Q. Y., Hung, J. C., Heber, D., et al. (2001). Inverse associations between plasma lycopene and other carotenoids and prostate cancer. Cancer Epidemiol Biomarkers Prev, 10, 749-756. (Pubitemid 32695154)
15. Giovannucci, E., Rimm, E. B., Liu, Y., et al. (2002). A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst, 94, 391-398. (Pubitemid 34257483)
16. Etminan, M., Takkouche, B., & Caamano-Isorna, F. (2004). The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev, 13, 340-345. (Pubitemid 38737456)
17. Peters, U., Leitzmann, M. F., Chatterjee, N., et al. (2007). Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev, 16, 962-968. (Pubitemid 46910098)
18. Mazdak, H., Mazdak, M., Jamali, L., et al. (2012). Determination of prostate cancer risk factors in Isfahan, Iran: a case-control study. Med Arh, 66, 45-48.
19. Salem, S., Salahi, M., Mohseni, M., et al. (2011). Major dietary factors and prostate cancer risk: a prospective multicenter case-control study. Nutr Cancer, 63, 21-27.
20. Jian, L., Xie, L. P., Lee, A. H., et al. (2004). Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer, 108, 130-135. (Pubitemid 37444455)
21. Kurahashi, N., Sasazuki, S., Iwasaki, M., et al. (2008). Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol, 167, 71-77.
22. Kikuchi, N., Ohmori, K., Shimazu, T., et al. (2006). No association between green tea and prostate cancer risk in Japanese men: the Ohsaki Cohort Study. Br J Cancer, 95, 371-373. (Pubitemid 44187600)
23. Zheng, J., Yang, B., Huang, T., et al. (2011). Green tea and black tea consumption and prostate cancer risk: an exploratory meta-analysis of observational studies. Nutr Cancer, 63, 663-672.
24. Jian, L., Lee, A. H., & Binns, C. W. (2007). Tea and lycopene protect against prostate cancer. Asia Pac J Clin Nutr, 16(Suppl 1), 453-457. (Pubitemid 46524644)
25. Jain, R. V., Mills, P. K., & Parikh-Patel, A. (2005). Cancer incidence in the south Asian population of California, 1988-2000. J Carcinog, 4, 21.
26. Donovan, M. J., Osman, I., Khan, F. M., et al. (2010). Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int, 105, 462-467.
27. Sircar, K., Yoshimoto, M., Monzon, F. A., et al. (2009). PTEN genomic deletion is associated with p-Akt and AR signaling in poorer outcome, hormone refractory prostate cancer. J Pathol, 218, 505-513.
28. Attar, R. M., Takimoto, C. H., & Gottardis, M. M. (2009). Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res, 15, 3251-3255.
29. Debes, J. D., & Tindall, D. J. (2004). Mechanisms of androgen-refractory prostate cancer. N Engl J Med, 351, 1488-1490. (Pubitemid 39315314)
30. Oh, H. Y., Leem, J., Yoon, S. J., et al. (2010). Lipid raft cholesterol and genistein inhibit the cell viability of prostate cancer cells via the partial contribution of EGFR-Akt/p70S6k pathway and downregulation of androgen receptor. Biochem Biophys Res Commun, 393, 319-324.
31. Basak, S., Pookot, D., Noonan, E. J., et al. (2008). Genistein downregulates androgen receptor by modulating HDAC6-Hsp90 chaperone function. Mol Cancer Ther, 7, 3195-3202.
32. Li, Y., Wang, Z., Kong, D., et al. (2008). Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells. J Biol Chem, 283, 27707-27716.
33. Jagadeesh, S., Kyo, S., & Banerjee, P. P. (2006). Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells. Cancer Res, 66, 2107-2115.
34. Li, Y., Ahmed, F., Ali, S., et al. (2005). Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res, 65, 6934-6942. (Pubitemid 41060733)
35. Wang, Y., Wang, H., Zhang, W., et al. (2013). Genistein sensitizes bladder cancer cells to HCPT treatment in vitro and in vivo via ATM/NF-kappaB/IKK pathway-induced apoptosis. PLoS One, 8, e50175.
36. Legg, R. L., Tolman, J. R., Lovinger, C. T., et al. (2008). Diets high in selenium and isoflavones decrease androgen-regulated gene expression in healthy rat dorsolateral prostate. Reprod Biol Endocrinol, 6, 57.
37. Fritz, W. A., Wang, J., Eltoum, I. E., et al. (2002). Dietary genistein downregulates androgen and estrogen receptor expression in the rat prostate. Mol Cell Endocrinol, 186, 89-99. (Pubitemid 34189782)
38. Phillip, C. J., Giardina, C. K., Bilir, B., et al. (2012). Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells. BMC Cancer, 12, 145.
39. Zhang, L., Li, L., Jiao, M., et al. (2012). Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog-Gli1 pathway. Cancer Lett, 323, 48-57.
40. Chang, K. L., Cheng, H. L., Huang, L. W., et al. (2009). Combined effects of terazosin and genistein on a metastatic, hormone-independent human prostate cancer cell line. Cancer Lett, 276, 14-20.
41. Burich, R. A., Holland, W. S., Vinall, R. L., et al. (2008). Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide, and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines. BJU Int, 102, 1458-1466.
42. Wang, Y., Raffoul, J. J., Che, M., et al. (2006). Prostate cancer treatment is enhanced by genistein in vitro and in vivo in a syngeneic orthotopic tumor model. Radiat Res, 166, 73-80. (Pubitemid 44051228)
43. Raffoul, J. J., Wang, Y., Kucuk, O., et al. (2006). Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer, 6, 107.
44. Singh-Gupta, V., Zhang, H., Banerjee, S., et al. (2009). Radiation-induced HIF-1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells. Int J Cancer, 124, 1675-1684.
45. Busby, M. G., Jeffcoat, A. R., Bloedon, L. T., et al. (2002). Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr, 75, 126-136. (Pubitemid 34013498)
46. Fischer, L., Mahoney, C., Jeffcoat, A. R., et al. (2004). Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia. Nutr Cancer, 48, 160-170. (Pubitemid 39045777)
47. Kumar, N. B., Cantor, A., Allen, K., et al. (2004). The specific role of isoflavones in reducing prostate cancer risk. Prostate, 59, 141-147. (Pubitemid 38481225)
48. Kumar, N. B., Krischer, J. P., Allen, K., et al. (2007). Safety of purified isoflavones in men with clinically localized prostate cancer. Nutr Cancer, 59, 169-175. (Pubitemid 350230734)
49. Kumar, N. B., Krischer, J. P., Allen, K., et al. (2007). A phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer, 59, 163-168. (Pubitemid 350230733)
50. Takimoto, C. H., Glover, K., Huang, X., et al. (2003). Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev, 12, 1213-1221. (Pubitemid 37499447)
51. Hussain, M., Banerjee, M., Sarkar, F. H., et al. (2003). Soy isoflavones in the treatment of prostate cancer. Nutr Cancer, 47, 111-117. (Pubitemid 38590881)
52. Bhuiyan, M. M., Li, Y., Banerjee, S., et al. (2006). Downregulation of androgen receptor by 3,3?-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res, 66, 10064-10072. (Pubitemid 44672060)
53. Hsu, J. C., Zhang, J., Dev, A., et al. (2005). Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells. Carcinogenesis, 26, 1896-1904. (Pubitemid 41631262)
54. Le, H. T., Schaldach, C. M., Firestone, G. L., et al. (2003). Plant-derived 3,3′-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J Biol Chem, 278, 21136-21145. (Pubitemid 36806427)
55. Li, Y., Wang, Z., Kong, D., et al. (2007). Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3?-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem, 282, 21542-21550. (Pubitemid 47099972)
56. Li, Y., Kong, D., Wang, Z., et al. (2011). Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells. Cancer Prev Res (Phila), 4, 1495-1506.
57. Li, Y., Chinni, S. R., & Sarkar, F. H. (2005). Selective growth regulatory and proapoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. Front Biosci, 10, 236-243. (Pubitemid 40543031)
58. Wang, T. T., Schoene, N. W., Milner, J. A., et al. (2012). Broccoli-derived phytochemicals indole-3-carbinol and 3,3′- diindolylmethane exerts concentration-dependent pleiotropic effects on prostate cancer cells: comparison with other cancer-preventive phytochemicals. Mol Carcinog, 51, 244-256.
59. Ahmad, A., Kong, D., Sarkar, S. H., et al. (2009). Inactivation of uPA and its receptor uPAR by 3,3′-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration. J Cell Biochem, 107, 516-527.
60. Azmi, A. S., Ahmad, A., Banerjee, S., et al. (2008). Chemoprevention of pancreatic cancer: characterization of Par-4 and itsmodulation by 3,3′ diindolylmethane (DIM). Pharm Res, 25, 2117-2124.
61. Beaver, L. M., Yu, T. W., Sokolowski, E. I., et al. (2012). 3,3′-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells. Toxicol Appl Pharmacol, 263, 345-351.
62. Chen, D., Banerjee, S., Cui, Q. C., et al. (2012). Activation of AMP-activated protein kinase by 3,3′-diindolylmethane (DIM) is associated with human prostate cancer cell death in vitro and in vivo. PLoS One, 7, e47186.
63. Duhon, D., Bigelow, R. L., Coleman, D. T., et al. (2010). The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells. Mol Carcinog, 49, 739-749.
64. Kong, D., Li, Y., Wang, Z., et al. (2007). Inhibition of angiogenesis and invasion by 3,3′-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res, 67, 3310-3319. (Pubitemid 46724870)
65. Kong, D., Heath, E., Chen, W., et al. (2012). Loss of let-7 upregulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One, 7, e33729.
66. Fan, S., Meng, Q., Auborn, K., et al. (2006). BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br J Cancer, 94, 407-426. (Pubitemid 43237565)
67. Sarkar, F. H., & Li, Y. (2004). Indole-3-carbinol and prostate cancer. J Nutr, 134, 3493S-3498S. (Pubitemid 39587595)
68. Kumi-Diaka, J. (2002). Chemosensitivity of human prostate cancer cells PC3 and LNCaP to genistein isoflavone and beta-lapachone. Biol Cell, 94, 37-44.
69. Kumi-Diaka, J., Merchant, K., Haces, A., et al. (2010). Genistein-selenium combination induces growth arrest in prostate cancer cells. J Med Food, 13, 842-850.
70. Rahman, K. M., Banerjee, S., Ali, S., et al. (2009). 3,3′- Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin downregulation. Cancer Res, 69, 4468-4475.
71. Reed, G. A., Sunega, J. M., Sullivan, D. K., et al. (2008). Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3′- diindolylmethane in healthy subjects. Cancer Epidemiol Biomarkers Prev, 17, 2619-2624.
72. Heath, E. I., Heilbrun, L. K., Li, J., et al. (2010). A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3′-diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. Am J Transl Res, 2, 402-411.
73. Hadad, N., & Levy, R. (2012). The synergistic anti-inflammatory effects of lycopene, lutein, beta-carotene, and carnosic acid combinations via redox-based inhibition of NF-kappaB signaling. Free Radic Biol Med, 53, 1381-1391.
74. Palozza, P., Colangelo, M., Simone, R., et al. (2010). Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines. Carcinogenesis, 31, 1813-1821.
75. Liu, X., Allen, J. D., Arnold, J. T., et al. (2008). Lycopene inhibits IGF-I signal transduction and growth in normal prostate epithelial cells by decreasing DHT-modulated IGF-I production in co-cultured reactive stromal cells. Carcinogenesis, 29, 816-823. (Pubitemid 351494170)
76. Zhang, X., Wang, Q., Neil, B., et al. (2010). Effect of lycopene on androgen receptor and prostate-specific antigen velocity. Chin Med J (Engl), 123, 2231-2236.
77. Tang, Y., Parmakhtiar, B., Simoneau, A. R., et al. (2011). Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels. Neoplasia, 13, 108-119.
78. Kumar, N. B., Besterman-Dahan, K., Kang, L., et al. (2008). Results of a randomized clinical trial of the action of several doses of lycopene in localized prostate cancer: administration prior to radical prostatectomy. Clin Med Urol, 1, 1-14.
79. Kucuk, O., Sarkar, F. H., Sakr, W., et al. (2001). Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev, 10, 861-868. (Pubitemid 32738598)
80. Kucuk, O., Sarkar, F. H., Djuric, Z., et al. (2002). Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med (Maywood), 227, 881-885. (Pubitemid 35340342)
81. Grainger, E. M., Schwartz, S. J., Wang, S., et al. (2008). A combination of tomato and soy products for men with recurring prostate cancer and rising prostate-specific antigen. Nutr Cancer, 60, 145-154. (Pubitemid 351451270)
82. Hastak, K., Gupta, S., Ahmad, N., et al. (2003). Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene, 22, 4851-4859. (Pubitemid 36981273)
83. Vayalil, P. K., & Katiyar, S. K. (2004). Treatment of epigallocatechin-3-gallate inhibits matrix metalloproteinases-2 and -9 via inhibition of activation of mitogen-activated protein kinases, c-jun, and NF-kappaB in human prostate carcinoma DU-145 cells. Prostate, 59, 33-42. (Pubitemid 38387841)
84. Siddiqui, I. A., Adhami, V. M., Afaq, F., et al. (2004). Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells. J Cell Biochem, 91, 232-242.
85. Ren, F., Zhang, S., Mitchell, S. H., et al. (2000). Tea polyphenols downregulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene, 19, 1924-1932. (Pubitemid 30219035)
86. Siddiqui, I. A., Asim, M., Hafeez, B. B., et al. (2011). Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J, 25, 1198-1207.
87. Lee, Y. H., Kwak, J., Choi, H. K., et al. (2012). EGCG suppresses prostate cancer cell growth modulating acetylation of androgen receptor by anti-histone acetyltransferase activity. Int J Mol Med, 30, 69-74.
88. Stearns, M. E., Amatangelo, M. D., Varma, D., et al. (2010). Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies: inhibition of metastatic tumor growth in severe combined immunodeficiency mice. Am J Pathol, 177, 3169-3179.
89. Stearns, M. E., & Wang, M. (2011). Synergistic effects of the green tea extract epigallocatechin-3-gallate and taxane in eradication of malignant human prostate tumors. Transl Oncol, 4, 147-156.
90. Siddiqui, I. A., Malik, A., Adhami, V. M., et al. (2008). Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associatedwith angiogenesis and metastasis. Oncogene, 27, 2055-2063. (Pubitemid 351442738)
91. Adhami, V. M., Malik, A., Zaman, N., et al. (2007). Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res, 13, 1611-1619. (Pubitemid 46450454)
92. Wang, P., Aronson, W. J., Huang, M., et al. (2010). Green tea polyphenols and metabolites in prostatectomy tissue: implications for cancer prevention. Cancer Prev Res (Phila), 3, 985-993.
93. McLarty, J., Bigelow, R. L., Smith, M., et al. (2009). Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila), 2, 673-682.
94. Mukhopadhyay, A., Bueso-Ramos, C., Chatterjee, D., et al. (2001). Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene, 20, 7597-7609. (Pubitemid 33111860)
95. Chaudhary, L. R., & Hruska, K. A. (2003). Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells. J Cell Biochem, 89, 1-5. (Pubitemid 36459092)
96. Kumar, A. P., Garcia, G. E., Ghosh, R., et al. (2003). 4-Hydroxy-3-methoxybenzoic acid methyl ester: a curcumin derivative targets Akt/NF kappa B cell survival signaling pathway: potential for prostate cancer management. Neoplasia, 5, 255-266. (Pubitemid 36754055)
97. Nakamura, K., Yasunaga, Y., Segawa, T., et al. (2002). Curcumin downregulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol, 21, 825-830.
98. Tsui, K. H., Feng, T. H., Lin, C. M., et al. (2008). Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells. J Androl, 29, 661-668.
99. Choi, H. Y., Lim, J. E., & Hong, J. H. (2010). Curcumin interrupts the interaction between the androgen receptor and Wnt/beta-catenin signaling pathway in LNCaP prostate cancer cells. Prostate Cancer Prostatic Dis, 13, 343-349.
100. Cabrespine-Faugeras, A., Bayet-Robert, M., Bay, J. O., et al. (2010). Possible benefits of curcumin regimen in combination with taxane chemotherapy for hormone-refractory prostate cancer treatment. Nutr Cancer, 62, 148-153.
101. Deeb, D., Xu, Y. X., Jiang, H., et al. (2003). Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Ther, 2, 95-103.
102. Shankar, S., Ganapathy, S., Chen, Q., et al. (2008). Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis, and angiogenesis. Mol Cancer, 7, 16.
103. Chendil, D., Ranga, R. S., Meigooni, D., et al. (2004). Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene, 23, 1599-1607. (Pubitemid 38406523)
104. Ide, H., Tokiwa, S., Sakamaki, K., et al. (2010). Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate, 70, 1127-1133.